Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Core Laboratories (CLB) EBT Margin (2022 - 2026)

Core Laboratories filings provide 5 years of EBT Margin readings, the most recent being 0.82% for Q1 2026.

  • On a quarterly basis, EBT Margin fell 229.0% to 0.82% in Q1 2026 year-over-year; TTM through Mar 2026 was 8.21%, a 7.0% decrease, with the full-year FY2025 number at 8.72%, down 10.0% from a year prior.
  • EBT Margin hit 0.82% in Q1 2026 for Core Laboratories, down from 9.56% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 13.59% in Q3 2025 to a low of 0.82% in Q1 2026.
  • Median EBT Margin over the past 5 years was 9.16% (2022), compared with a mean of 7.96%.
  • Biggest five-year swings in EBT Margin: skyrocketed 485bps in 2023 and later tumbled -250bps in 2025.
  • Core Laboratories' EBT Margin stood at 9.83% in 2022, then fell by -13bps to 8.55% in 2023, then increased by 4bps to 8.93% in 2024, then grew by 7bps to 9.56% in 2025, then crashed by -109bps to 0.82% in 2026.
  • The last three reported values for EBT Margin were 0.82% (Q1 2026), 9.56% (Q4 2025), and 13.59% (Q3 2025) per Business Quant data.